New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells
(2003) Tissue Antigens : immune response genetics — Vol. 62, n° 5, p. 426-432 (2003)
Files
KOBAYASHI_TA2003.pdf
Restricted Access - Adobe PDF
- 182.32 KB
Details
- Authors
- Abstract
- 'Cancer-germline' genes such as those of the MAGE family are expressed in many tumors and in male germline cells, but are silent in other normal tissues. They encode shared tumor-specific antigens, which have been used in small therapeutic vaccination trials of cancer patients. Gene MAGE-4, which is expressed in more than 50% of carcinomas of esophagus, head and neck, lung, and bladder, has two known alleles. Using PCR amplifications and digestions of the amplified product, we found that one third of the MAGE-4-positive samples expressed MAGE-4a. We folded HLA-A1 tetramers with peptide MAGE-4a(169-177) EVDPASNTY, which is homologous to MAGE-1- and MAGE-3-encoded peptides recognized on HLA-A1 by cytolytic T lymphocytes. Blood lymphocytes from an individual without cancer were directly labelled with these A1/MAGE-4 tetramers. The very rare cells that were stained were sorted by flow cytometry and cloned. We isolated a cytolytic T-lymphocyte clone that lyzed specifically cells pulsed with this MAGE-4 peptide and HLA-A1 tumor cells expressing MAGE-4a, demonstrating that this antigenic peptide is processed efficiently in tumor cells. This peptide might therefore be useful for therapeutic antitumoral vaccination.
- Affiliations
Citations
Kobayashi, T., Lonchay, C., Colau, D., Demotte, N., Boon, T., & van der Bruggen, P. (2003). New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells. Tissue Antigens : immune response genetics, 62(5), 426-432. https://doi.org/10.1034/j.1399-0039.2003.00123.x (Original work published 2003)